Last reviewed · How we verify
NCT05800093: PREDICT-CVD
Proteomics and Genomics Combined With CT to Predict CVD
trial in Coronary Artery Disease Progression in 310 participants. Participants enrolled and being followed up; not accepting new ones.
30 January 2026
Quick facts
| Lead sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 310 |
| Start date | 12 January 2023 |
| Primary completion | 30 January 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across Netherlands |
Conditions studied
- Coronary Artery Disease Progression — all drugs for Coronary Artery Disease Progression →
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →
Who can join
Adults 50 to 75, any sex, with Coronary Artery Disease Progression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Polygenic Risk Is Associated With Long-Term Coronary Plaque Progression and High-Risk Plaque.
Nurmohamed NS, Shim I, Gaillard EL, Ibrahim S, et al · · 2024 · cited 10× · PMID 39152960 · DOI 10.1016/j.jcmg.2024.06.015
Verify or expand the search:
- PubMed search for NCT05800093
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease Progression
Currently open trials in the same condition.
- NCT06040073 — Natural History of Coronary Atherosclerosis · recruiting
- NCT04772768 — Prior CABG Patients Evaluated for Saphenous VeIn grAft DysfUnction and Progression of Coronary arTery Disease · recruiting
- NCT03349385 — Registry of Secondary Revascularization · active not recruiting
Other Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials
Trials by the same sponsor.
- NCT07301021 — Velopharyngeal Insufficiency After Maxillomandibular Advancement Osteotomy in Obstructive Sleep Apnea Patients · not yet recruiting
- NCT07359482 — sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 · Phase 3 · not yet recruiting
- NCT07457957 — Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents · NA · not yet recruiting
- NCT06909045 — Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease · NA · recruiting
- NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05800093 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Last refreshed: 2 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05800093.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing